This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum
by Moumi Mondal
HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.
Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures
by Zacks Equity Research
SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.
ISRG SP Platform's Expansion in Korea and Europe Gains Traction
by Indrajit Bandyopadhyay
Intuitive Surgical's SP platform gains momentum with 112% growth in Korea and steady European uptake, highlighting global adoption despite regional headwinds.
Top Stock Reports for HSBC, American Express & TotalEnergies
by Mark Vickery
HSBC, American Express and TotalEnergies top today's Zacks research highlights, with strategies and risks shaping their outlooks.
Stryker Expands R&D Facility in India to Boost Medtech Innovation
by Zacks Equity Research
SYK expands its Bangalore R&D hub to accelerate robotics, AI and digital health innovation while deepening ties with India's talent pool.
SNN vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNN vs. SYK: Which Stock Is the Better Value Option?
SYK Partners With Siemens Healthineers to Boost Stroke, Aneurysm Care
by Zacks Equity Research
Stryker teams with Siemens Healthineers to develop a robotic ecosystem aimed at advancing stroke and aneurysm care.
SNN or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SNN vs. SYK: Which Stock Is the Better Value Option?
Investing in the Age of Longevity: Silver Economy Stocks in Focus
by Urmimala Biswas
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Akero Therapeutics, Inc. (AKRO) and Stryker (SYK) have performed compared to their sector so far this year.